Edwards Lifesciences Corp: (NYSE: EW)

$64.30

-1.70 (-2.58%)

Volume 2,086,729

May 22 04:00 PM ET

Zacks Rank: 4-Sell

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		64.07 - 66.95
	
		52wk Low - High
		62.34 - 110.79
	
		Previous Close
		66.00
	
		Avg. Volume
		1,798,814
	
		Industry
		MED PRODUCTS
	
		Market Cap
		7.36 B
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.43
	
		PE (Forward)
		21.08
	
		Current Year Est.
		3.05
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		184 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 04/24/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            21.08
                        
                            PEG Ratio
                            1.22
                        
                            Current Year Est.
                            3.05
                        
                            Current Quarter Estimate
                            0.77
                        
                            Most Accurate Estimate
                            0.77
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-23-2013
                        
                            EPS Last Year
                            2.87
                        
                            Expected Earnings Growth
                            17.28%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Edwards Lifesciences Corp. a leader in advanced cardiovascular disease treatments, is the number-one heart valve company in the world and the global leader in acute hemodynamic monitoring. Headquartered in Irvine, Calif., Edwards focuses on specific cardiovascular disease states including heart valve disease, peripheral vascular disease and critical care technologies. The company's global brands, which are sold in approximately hundred countries, include Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, LifeStent, PERIMOUNT Magna and Swan-Ganz. Edwards Lifesciences, Carpentier-Edwards, Cosgrove-Edwards, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office. LifeStent is a trademark of Edwards Lifesciences AG and is registered in the United States Patent and Trademark Office.   
Full EW Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
EW Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.77	0.70	3.05	3.68
Number of Estimates	13	12	14	13
Low Estimate	0.75	0.66	3.00	3.46
High Estimate	0.78	0.73	3.08	NA
Year Ago EPS	0.67	0.58	2.69	3.05
EPS Growth	14.35%	20.83%	13.41%	20.75%

More EW Estimates

Average Earnings Estimates for EW

EPS Growth for EW

Industry Analysis

Name	Symbol	Previous Close
EDWARDS LIFESCI	EW	64.30
ATRICURE INC	ATRC	9.14
CONCEPTUS INC	CPTS	30.94
INVIVO THERAPT	NVIV	2.90
TRANS1 INC	TSON	1.80
ABAXIS INC	ABAX	43.51
ADVAXIS INC	ADXS	0.04
BAXTER INTL	BAX	72.30
BIO-RAD LABS -A	BIO	115.39
BIOLIFE SOL INC	BLFS	0.37

Sector:Medical>> Industry:MED PRODUCTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Edwards Lags on Earnings & Rev

Apr 24, 2013

FDA Clears Affinity, Boosts MDT's Biz

Apr 03, 2013

Hanger Stays Neutral

Mar 22, 2013

Still Neutral on Omnicell

Mar 22, 2013

Merge introduces Merge OrthoPACS

Mar 22, 2013

Positive Data for St Jude's Trifecta

Mar 20, 2013

Pediatric Exclusivity for Hospira's Drug

Mar 19, 2013

Stryker Launches Iconix

Mar 19, 2013

More EW Zacks Commentary

Financials

EPS TTM	2.87
Sales	1,900
Net Income	373
Price/Earnings	22.40
Price/Book	4.62
Price/Cash Flow	19.77
Price/Sales	3.80

More EW Financials

News

East West Adopts Advance Notice Policy - Marketwire

May 23, 2013

East West Adopts Advance Notice Policy - Marketwire Canada

May 23, 2013

Global Cardiac Bio Implant Devices Market Forecast, Clinical Trials, M&A - M2

May 23, 2013

Short-term Underperformance Detected in Shares of ABIOMED in the Health Care Equipment Industry (ABMD, EW, DXCM, WMGI, BCR) - Financial News Network Online - News Corner

May 22, 2013

Analysis of Relative Performance in the Health Care Equipment Industry for Shares of Thoratec (THOR, HTWR, EW, ABMD, CFN) - Financial News Network Online - News Corner

May 21, 2013

Edwards Lifesciences Makes a Move: Down 1.5% - Financial News Network Online - Market Movers

May 21, 2013

Positive Patient Outcomes at One Year With Edwards Sapien XTTranscatheter Valve - Marketwire

May 21, 2013

Edwards Lifesciences (EW) Trading Near $65.97 Support Level - Freshbrewedmedia

May 17, 2013

See All News Stories on EW

Broker Recommendations

Current ABR	2.22
ABR (Last Week)	2.22
# of recs in ABR	18
Average Target Price	80.20
Industry Rank by ABR	184 out of 265
Rank in Industry	63 out of 73

More EW Broker Recommendations

Day Low - High	64.07 - 66.95
52wk Low - High	62.34 - 110.79
Previous Close	66.00
Avg. Volume	1,798,814
Industry	MED PRODUCTS
Market Cap	7.36 B
Div - Yield	0.00 - 0.00
Beta	0.43
PE (Forward)	21.08
Current Year Est.	3.05
Quarterly Earnings ESP	0.00%

PE (Forward)	21.08
PEG Ratio	1.22
Current Year Est.	3.05
Current Quarter Estimate	0.77
Most Accurate Estimate	0.77
Earnings ESP	0.00%
Next Earnings Report Date	07-23-2013
EPS Last Year	2.87
Expected Earnings Growth	17.28%

Username: Password:

Remember me [?]

Edwards Lifesciences Corp: (NYSE: EW)

$64.30

-1.70 (-2.58%)

Volume 2,086,729

May 22 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED PRODUCTS

Zacks Commentary

Financials

News

Broker Recommendations